David A. Sallman1, Rafael Bejar2, Guillermo Montalban-Bravo3, Sandra E. Kurtin4, Alan F. List5, Guillermo Garcia-Manero3, Stephen D. Nimer6, Casey L. O'Connell7, Dale Schaar8, Janice Butchko9, Tracey Iraca9, Stephanie Searle10
1Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
2Division of Hematology and Oncology, MDS Center of Excellence, University of California, San Diego, La Jolla, CA
3Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
4University of Arizona Cancer Center, University of Arizona, Tucson, AZ
5Precision BioSciences, Durham, NC
6Department of Medicine, Biochemistry & Molecular Biology, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL
7Jane Anne Nohl Division of Hematology, University of Southern California, Los Angeles, CA
8Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
9MDS Foundation, Yardville, NJ
10Mechanisms in Medicine Inc., Toronto, ON, Canada
Leuk Res Rep. 2022 May;17:100328.
DOI: 10.1016/j.lrr.2022.100328
David A. Sallman1, Rafael Bejar2, Guillermo Montalban-Bravo3, Sandra E. Kurtin4, Alan F. List5, Guillermo Garcia-Manero3, Stephen D. Nimer6, Casey L. O'Connell7, Dale Schaar8, Janice Butchko9, Tracey Iraca9, Stephanie Searle10
1Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
2Division of Hematology and Oncology, MDS Center of Excellence, University of California, San Diego, La Jolla, CA
3Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX
4University of Arizona Cancer Center, University of Arizona, Tucson, AZ
5Precision BioSciences, Durham, NC
6Department of Medicine, Biochemistry & Molecular Biology, University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center, Miami, FL
7Jane Anne Nohl Division of Hematology, University of Southern California, Los Angeles, CA
8Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
9MDS Foundation, Yardville, NJ
10Mechanisms in Medicine Inc., Toronto, ON, Canada
Leuk Res Rep. 2022 May;17:100328.
DOI: 10.1016/j.lrr.2022.100328
This educational activity has been developed by the Myelodysplastic Syndromes Foundation, Inc. and Mechanisms in Medicine Inc.
This activity is supported by an educational grant from Acceleron Pharma, Bristol-Myers Squibb, Celgene Corporation, Jazz Pharmaceuticals, Novartis Pharmaceuticals, and Takeda Oncology.
This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their healthcare professionals for optimal outcomes.